251 related articles for article (PubMed ID: 26686089)
21. c-Myc promotes tumor proliferation and anti‑apoptosis by repressing p21 in rhabdomyosarcomas.
Zhang J; Song N; Zang D; Yu J; Li J; Di W; Guo R; Zhao W; Wang H
Mol Med Rep; 2017 Oct; 16(4):4089-4094. PubMed ID: 28765944
[TBL] [Abstract][Full Text] [Related]
22. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade.
Liu JL; Mao Z; LaFortune TA; Alonso MM; Gallick GE; Fueyo J; Yung WK
Cancer Res; 2007 Nov; 67(22):11054-63. PubMed ID: 18006852
[TBL] [Abstract][Full Text] [Related]
23. Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor.
Prince S; Carreira S; Vance KW; Abrahams A; Goding CR
Cancer Res; 2004 Mar; 64(5):1669-74. PubMed ID: 14996726
[TBL] [Abstract][Full Text] [Related]
24. TBX2 and TBX3: the special value for anticancer drug targets.
Lu J; Li XP; Dong Q; Kung HF; He ML
Biochim Biophys Acta; 2010 Dec; 1806(2):268-74. PubMed ID: 20624445
[TBL] [Abstract][Full Text] [Related]
25. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
26. Tbx2 represses expression of Connexin43 in osteoblastic-like cells.
Chen JR; Chatterjee B; Meyer R; Yu JC; Borke JL; Isales CM; Kirby ML; Lo CW; Bollag RJ
Calcif Tissue Int; 2004 Jun; 74(6):561-73. PubMed ID: 15354864
[TBL] [Abstract][Full Text] [Related]
27. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
28. The Expression of c-Myb Correlates with the Levels of Rhabdomyosarcoma-specific Marker Myogenin.
Kaspar P; Zikova M; Bartunek P; Sterba J; Strnad H; Kren L; Sedlacek R
Sci Rep; 2015 Oct; 5():15090. PubMed ID: 26462877
[TBL] [Abstract][Full Text] [Related]
29. New insights into signalling-pathway alterations in rhabdomyosarcoma.
Zhu B; Davie JK
Br J Cancer; 2015 Jan; 112(2):227-31. PubMed ID: 25211658
[TBL] [Abstract][Full Text] [Related]
30. Selective Targeting of Myoblast Fusogenic Signaling and Differentiation-Arrest Antagonizes Rhabdomyosarcoma Cells.
Granados VA; Avirneni-Vadlamudi U; Dalal P; Scarborough SR; Galindo KA; Mahajan P; Galindo RL
Cancer Res; 2019 Sep; 79(18):4585-4591. PubMed ID: 31331911
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration.
Sarver AL; Li L; Subramanian S
Cancer Res; 2010 Dec; 70(23):9570-80. PubMed ID: 21118966
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel genes expressed during rhabdomyosarcoma differentiation using cDNA microarrays.
Carey KA; Segal D; Klein R; Sanigorski A; Walder K; Collier GR; Cameron-Smith D
Pathol Int; 2006 May; 56(5):246-55. PubMed ID: 16669873
[TBL] [Abstract][Full Text] [Related]
33. Smad4 and ERK2 stimulated by transforming growth factor beta1 in rhabdomyosarcoma.
Guo H; Zhang HY; Wang SL; Ye L; Yang GH; Bu H
Chin Med J (Engl); 2007 Mar; 120(6):515-21. PubMed ID: 17439748
[TBL] [Abstract][Full Text] [Related]
34. Roles of phosphatase and tensin homolog in skeletal muscle.
Shan T; Liu J; Xu Z; Wang Y
J Cell Physiol; 2019 Apr; 234(4):3192-3196. PubMed ID: 30471096
[TBL] [Abstract][Full Text] [Related]
35. Hedgehog/Patched-associated rhabdomyosarcoma formation from delta1-expressing mesodermal cells.
Nitzki F; Cuvelier N; Dräger J; Schneider A; Braun T; Hahn H
Oncogene; 2016 Jun; 35(22):2923-31. PubMed ID: 26387541
[TBL] [Abstract][Full Text] [Related]
36. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway.
Wang F; Li L; Chen Z; Zhu M; Gu Y
Int J Mol Med; 2016 May; 37(5):1421-8. PubMed ID: 26951965
[TBL] [Abstract][Full Text] [Related]
38. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer.
Wang Y; He X; Ngeow J; Eng C
Hum Mol Genet; 2012 Feb; 21(3):569-76. PubMed ID: 22021428
[TBL] [Abstract][Full Text] [Related]
39. TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma.
Shah AM; Guo L; Morales MG; Jaichander P; Chen K; Huang H; Cano Hernandez K; Xu L; Bassel-Duby R; Olson EN; Liu N
Sci Adv; 2023 Apr; 9(17):eade8184. PubMed ID: 37115930
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
